TABLE 2.
Association between the genetic score and incident venous thromboembolism in vaccinated and reference cohorts
| Number of people | Number of cases | Incidence rate (95% CI) a | Primary PRS | Sensitivity PRS | ||
|---|---|---|---|---|---|---|
| Unadjusted hazard ratio (95% CI) b | Adjusted hazard ratio (95% CI) b | Adjusted hazard ratio (95% CI) b | ||||
| Vaccinated cohorts | ||||||
| 28 days after one dose | 359 310 | 88 | 0.88 (0.70–1.08) | 1.41 (1.15–1.73) | 1.41 (1.15–1.73) | 1.38 (1.13–1.70) |
| 90 days after one dose | 359 310 | 299 | 0.92 (0.82–1.04) | 1.36 (1.22–1.52) | 1.36 (1.22–1.52) | 1.34 (1.20–1.50) |
| 28 days after two doses | 357 018 | 78 | 0.78 (0.62–0.97) | 1.31 (1.05–1.63) | 1.30 (1.04–1.61) | 1.25 (1.00–1.55) |
| 90 days after two doses | 357 018 | 269 | 0.83 (0.74–0.96) | 1.34 (1.19–1.50) | 1.33 (1.18–1.49) | 1.29 (1.15–1.46) |
| Historically unvaccinated cohorts | ||||||
| Whole UKBB (prepandemic) | 391 752 | 1078 | 0.76 (0.71–0.80) | 1.36 (1.29–1.45) | 1.36 (1.28–1.44) | 1.34 (1.26–1.42) |
| Whole UKBB (early pandemic) | 387 829 | 846 | 0.80 (0.74–0.85) | 1.35 (1.26–1.44) | 1.34 (1.26–1.44) | 1.27 (1.19–1.36) |
| Infected cohorts | ||||||
| 28 days after infection | 24 700 | 155 | 25.6 (21.8–30.0) | 1.29 (1.10–1.51) | 1.32 (1.13–1.55) | 1.32 (1.12–1.55) |
| 90 days after infection | 24 700 | 186 | 10.9 (9.4–12.6) | 1.27 (1.10–1.46) | 1.29 (1.12–1.49) | 1.28 (1.11–1.48) |
Note: The prepandemic was defined as the period between March 23, 2019, and March 23, 2020. The early pandemic was defined as the period between March 23, 2020, and December 1, 2020. The negative control outcome was incident diabetes.
Abbreviations: PRS, polygenic risk score; UKBB, UK Biobank.
a
Per 100 000 person‐days.
b
Per 1‐SD increase of PRS.